Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrthoLogic

This article was originally published in The Gray Sheet

Executive Summary

Firm no longer co-markets Hyalgan osteoarthritis treatment, as was reported in "The Gray Sheet" (July 9, 2001, p. 9); the arrangement expired at the end of 2000 (1"The Gray Sheet" Feb. 5, 2001, p. 4)

You may also be interested in...



Smith & Nephew's Supartz Is Third Player In HA Osteoarthritis Market

Smith & Nephew's 400-rep sales force plans to emphasize the extensive clinical experience behind the firm's Supartz hyaluronic acid-based injectable treatment for osteoarthritis of the knee in marketing the product to orthopedic surgeons.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

UsernamePublicRestriction

Register

MT015158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel